A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ANTLER)
Details
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Eligibility
You can join if...
AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?
Please note, this is not a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.
Inclusion Requirements
You can participate in this study if you
Are at least 18 years old
Understand and are willing to sign informed consent.
Exclusion Requirements
You cannot participate in this study if you
Are pregnant or breastfeeding
Have history of infection with human immunodeficiency virus (HIV)
Have active hepatitis B or C virus infection